NASDAQ (USD): Cognition Therapeutics, Inc. (CGTX)
Last Price
0.58
Today's Change
+0.125 (27.47%)
Day's Change
0.552 - 1.29
Trading Volume
287,727,444
You are setting up a price and signal alert with 15 minutes delay. Click here to enjoy real-time price and signal alerts.
T4Q
31-Mar-2021
2020
2019
2018
2017
Cash from operating activities
238
-1.64%
1000
+11.55%
110
+81.66%
900
-13.16%
600
+235.36%
MQ Chat
Send individual or group chats with anyone on i3investor
MQ Trader
Earn MQ Points while trading with MQ Trader
MQ Affiliate
Earn side income from Affiliate Program
MQdemy
Online learning and teaching marketplace
1
CEO Morning Brief
Trump Transition Team Plans Sweeping Rollback of Biden's EV, Emissions Policies
2
Nasdaq Tops NYSE in Listings for Sixth Straight Year as IPO Optimism Grows
3
Goldman Sachs Economists See Fed Skipping a Rate Cut in January
4
Cocoa Soars to Fresh Record in Blow to World’s Chocolate Supply
5
US Retail Sales Beat Expectations in November
#
Stock
Score
TSLA
Tesla, Inc.
SOUN
SoundHound AI, Inc.
615
NVDA
NVIDIA Corporation
476
AVGO
Broadcom Inc.
461
OKLO
Oklo Inc.
307
6
MSS
Maison Solutions Inc. Class A Common Stock
7
AGN
230
8
AAPL
Apple Inc.
9
IRIS
184
10
ETE
153
Last
Change
Volume
LITM
0.82
+0.637
1,191,454,245
SLNA
0.03
-0.008
379,091,456
CYXT
0.065
0.00
369,807,727
TNXP
0.365
+0.031
299,491,731
CGTX
+0.125
RGTI
10.69
-0.44
274,747,393
128.91
-1.48
249,755,855
UWT
0.164
-0.002
244,137,454
QUBT
25.61
+8.82
224,758,415
QBTS
8.96
+0.56
210,691,907
RTLA
209.90
+74.87
0
QMCO
60.02
+36.30
21,980,388
ACSG
33.28
+33.28
99,050
EMSA
140.77
+30.77
EMLB
80.80
+30.30
NOVVU
41.00
+28.85
17,976
NOVV
37.00
+23.46
205,220
EDTX
63.24
+20.01
603,885
YNDX
18.94
+18.94
EDTXU
57.22
+18.22
1,071
BRK-A
670,737.68
-13,382.312
1,520
MELI
1,774.05
-343.25
2,940,447
NVR
8,217.15
-251.34
32,262
BKNG
4,943.35
-211.61
297,272
MSTR
1,309.00
-138.99
2,237,917
BH-A
1,199.37
-118.52
150
MKL
1,395.13
-102.30
318,280
1,716.38
-92.74
749,562
LOWC
30.18
-92.412
1,236,074
TPL
1,114.46
-89.20
161,433
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....